Imperial College London joins Parkinson's biomarker study; Edwards wins FDA nod for blood volume Dx monitor;

> Imperial College London will take part in a biomarker study funded by the Michael J. Fox Foundation for Parkinson's Research that is looking at the genetics of Parkinson's disease. Release

> Eurofins Scientific forked over $255 million to buy ViraCor-IBT Laboratories, a specialty diagnostic testing laboratory focused on the transplant market that services more than 550 institutional clients and over 4,000 affiliated clinicians across the U.S. Release

> The University of Milan and other Italian organizations have sealed some new cancer biomarker deals with a number of U.K. firms. Story (reg. req)

> Edwards Lifesciences ($EW) won FDA clearance for a new noninvasive diagnostic monitor for blood volume and flow to make sure post-surgery patients are getting enough oxygen in their organs and tissues. Item

> A new study points to plasma connective tissue growth factor as a possible asthma biomarker. Story

> Medical imaging company BioClinica ($BIOC) plans to showcase brain-imaging advances it has made in Alzheimer's disease clinical trials at an upcoming conference in Copenhagen. Release

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.